A meta-analysis of 10-year data from 4 randomized trials found no significant difference in all-cause mortality between DES PCI and CABG. Long-term follow-up supports considering both approaches for suitable patients.
The ARTICA meta-analysis investigated the safety and effectiveness of coronary revascularisation in patients undergoing TAVI, providing comprehensive insights into the optimal role of PCI. The findings suggest a potential benefit of selective, physiology-informed PCI in patients with severe aortic stenosis and CAD undergoing TAVI.
A subgroup analysis of the CHAMPION-AF trial reveals that left atrial appendage closure (LAAC) efficacy and safety are not affected by age, suggesting it can be considered for suitable candidates regardless of age. The choice between LAAC and DOAC should be made on an individualized basis in a shared decision-making process with patients.
Roxana Mehran is recognized for her impactful work on improving outcomes for patients undergoing interventional procedures. She has contributed to major trials, including the TWILIGHT trial, and advocates for women in medicine through initiatives like Women As One.
EuroPCR 2026 will feature 4 days of quality content, case-based learning sessions, and interactive formats. The course is designed for all levels of experience, covering topics in interventional cardiology, nursing, and research. EuroPCR aims to advance the quality of interventional practice and provide a transformative experience.
The RESIL-Card tool helps hospital cardiovascular professionals and stakeholders assess and strengthen care pathways, ensuring continuity of care during crises. The tool offers a structured self-assessment framework, identifying concrete actions to maintain care continuity and patient safety.
The Journal EuroIntervention has recorded an impressive Impact Factor of 9.5, making it one of the most cited publications in interventional cardiology. This achievement is attributed to the journal's commitment to publishing high-quality clinical articles and expert commentaries.
The 4D-ACS trial showed a 49% reduction in net adverse clinical events and a 77% decrease in bleeding events with one-month DAPT followed by prasugrel 5mg monotherapy, demonstrating enhanced safety without compromising ischaemic protection for East Asian ACS patients.
A meta-analysis of PROTECTED TAVR and BHF PROTECT-TAVI trials reveals no significant difference between control arms with and without cerebral embolic protection devices during TAVI. This conclusion challenges the use of CEP devices in TAVI procedures.
The FAITAVI trial found that FFR-guided PCI reduced major adverse cardiac and cerebrovascular events at 12-month follow-up in patients with intermediate coronary artery disease undergoing TAVI. FFR-guided PCI was associated with lower rates of all-cause death and ischaemia-driven target vessel revascularisation.
Professor Lars Wallentin and Professor Stefan James will receive the award on behalf of a wider team of Swedish cardiovascular registry experts who have advanced cardiovascular medicine through SWEDEHEART and SCAAR registries. The award recognises their contributions to improving patient care in Sweden and globally.
The RESIL-Card project is piloting its resilience assessment tool in selected European countries to evaluate its effectiveness, usability, and relevance for healthcare professionals. The tool provides structured guidance for assessing and improving the resilience of cardiovascular care pathways.
The EuroPCR 2025 conference will cover interventions for coronary and peripheral vessels, valvular disease, heart failure, hypertension, and stroke. Sessions on complex topics will be held throughout the four-day programme, with a focus on sharing solutions.
Over 11,000 participants from around the globe will share knowledge and skills on interventions for coronary and peripheral vessels at EuroPCR 2024. The course features 66 Late-Breaking Trials and Hotlines, as well as simulation-based learning sessions and focus on imaging.
The use of drug-coated balloons (DCBs) in coronary angioplasty is gaining importance, particularly for treating in-stent restenosis. Newer devices are being developed, and upcoming trials aim to enhance the evidence base for DCB treatment, especially in patients with de novo disease.
International emergency medical services received the Andreas Grüntzig Ethica Award for their exceptional contribution to interventional cardiovascular medicine and patient care. The award highlights the importance of EMS networks in facilitating effective treatment of STEMI patients.
The latest clinical evidence on TAVI in younger patients with aortic stenosis will be discussed, including factors that determine the choice between TAVI and surgical aortic valve replacement. Valve design and implantation technique can also influence long-term outcomes and future treatment options.
EuroPCR 2023 brings together experts in interventional cardiovascular medicine to share knowledge, skills, and innovations. The event features 220 workshops, live-streamed sessions, and a scientific abstract competition.
The Nurses and Allied Professionals community is being recognized for their dedication and skills in advancing cardiovascular care. The Andreas Grüntzig Ethica Award celebrates their expertise, physical presence, and impact on patient care.
The EuroPCR 2021 digital platform hosted 8,091 physicians from over 126 countries, offering a prime learning experience through real-time exchange and interactivity. The event featured 67 late-breaking trials, live chats, and practical Training Workshops, with 3-months access to the replayed Programme.
The Cool AMI EU pivotal trial evaluated the safety and effectiveness of systemic mild hypothermia as an adjunctive therapy to primary PCI in patients with anterior STEMI. The trial showed significant differences between treatment groups, including longer randomization-to-balloon time and total ischemic time.
The CASTLE study investigated the role of imaging-guided percutaneous cardiac intervention (PCI) in clinical outcomes difference between ultra-thin strut biodegradable polymer sirolimus-eluting stent (Orsiro) and durable polymer everolimus-eluting stents (Xience). The results show no significant differences in target lesion failure rat...
A new meta-analysis of 19,806 patients with chronic coronary syndromes found a statistically significant 21% relative risk reduction in cardiac death with revascularization plus medical therapy. The study also showed a parallel significant reduction in spontaneous myocardial infarction, but no difference in all-cause death.
A randomized trial demonstrates that TAVI with a self-expanding supraannular bioprosthesis is comparable to surgical aortic valve replacement in terms of mortality and stroke risk at 24 months. Additionally, the study reveals that TAVI is superior to surgery in terms of valve hemodynamics but not in pacemaker implantation rates.
A randomized trial comparing a new, thin-strut bioresorbable scaffold with a metallic stent showed non-inferiority of the bioresorbable scaffold in terms of late lumen loss and covered struts. The trial's results may revitalize the concept of bioresorbable scaffolds.
The EBC MAIN trial found no significant difference in one-year clinical outcomes between planned single stenting and upfront two-stent techniques for true bifurcation distal left main disease. The primary composite endpoint of death, myocardial infarction, and target lesion revascularization occurred at a rate of 14.7% in the provision...
Dr. Morice's career spans over four decades, with a focus on pioneering the use of antiplatelet drugs in PCI and promoting education and training among young professionals. She has also been a key advocate for gender equality in medicine, co-founding Women as One to promote talent in cardiology.
We CARE aims to empower stakeholders to provide effective and timely cardiac care through knowledge, education, and training. The joint initiative seeks to restore patients' faith in pursuing timely medical treatment, particularly during the COVID-19 pandemic.
The PCR Valves e-Course will unite global experts in valvular heart disease for a 3-day digital initiative. Key findings include virtual LIVE demonstrations and classroom environment workshops offering simulation-based learning on cardiac anatomy and pathophysiology.
A new non-invasive ultrasound therapy has been shown to be safe and effective in improving heart condition and clinical status of patients with severe symptomatic aortic valve stenosis. The therapy, developed by Cardiawave, widens the aortic valve opening using high-intensity ultrasounds, eliminating the need for invasive treatment.
The systematic two-stent approach significantly improved clinical outcomes compared to provisional stenting in patients with complex coronary bifurcation lesions. TVMI and TLR rates were lower in the two-stent group, while cardiac death rates were similar.
A large-scale analysis of mitral valve-in-valve (ViV) and valve-in-ring (ViR) found significant residual mitral stenosis and regurgitation in patients, leading to repeat valve replacements. The four-year Kaplan-Meier survival rate was 62.5% for ViV vs. 49.5% for ViR.
A meta-analysis of randomized trials found routine revascularization associated with lower non-procedural MI and unstable angina risk, but higher procedural MI rates. The benefits of routine revascularization compared to medical therapy are still uncertain.
The DynamX Bioadaptor combines acute performance with unique benefits of arterial 'uncaging', allowing for positive adaptive remodeling and reduced target vessel revascularization. This innovation in device design may mitigate the persistent annualized event rate beyond one year.
A pooled analysis of DEFINE FLAIR and iFR SWEDEHEART trials reveals similar safety profiles for iFR and FFR in deferring revascularisation. However, FFR-based deferral shows a strong interaction with age, which may be related to varying age-related responses to adenosine.
The ISCHEMIA trial results show that initial medical therapy is more beneficial than invasive interventions like revascularization in reducing hard outcomes and improving health outcomes for patients with chronic coronary syndromes. The study's findings have significant implications for current guidelines and future clinical practices.
In a multicenter randomized controlled trial, crossover patients who received renal denervation due to elevated ambulatory blood pressures experienced significant reductions in daytime ambulatory systolic BP. The blood pressure lowering effect was consistent with primary RADIANCE-HTN SOLO results.
New trials and the Global Symplicity Registry report consistent and clinically meaningful ambulatory and office BP reductions in patients with mild to moderate uncontrolled hypertension. RDN is effective and durable in these high-risk populations, with low rates of new-onset end-stage renal disease.
Chronic diseases account for 50-75% of global health care costs, with current delivery models poorly constructed to manage these conditions. Healthcare systems must develop strategies to care for severely ill patients while continuing treatment for those with chronic disease.
A large-scale assessment of long-term survival and reintervention after aortic ViV found that smaller failed bioprostheses were associated with lower survival rates. The type of transcatheter valve used also influenced the need for reintervention, with EBEV being a significant risk factor.
The American Heart Association statement addresses the controversy surrounding paclitaxel-eluting stents and drug-coated balloons in peripheral interventions. Despite a 2018 meta-analysis suggesting increased mortality with paclitaxel exposure, individual sponsor-driven analyses have failed to replicate these findings.
The EAPCI has generated consensus statements detailing the clinical utility of IC imaging, based on existing clinical evidence and contemporary best practice. IC imaging is beneficial for guiding percutaneous coronary interventions (PCI) and understanding stent failure mechanisms.
The 11,800 participants shared the latest developments and best practices in treating cardiovascular conditions, including coronary and valvular heart disease and stroke. EuroPCR 2017 also celebrated the 40th anniversary of angioplasty with an exhibition tracing its pioneering history.
Seven novel bioresorbable stent technologies were reported to deliver low medium-term event rates and favorable laminar flow. The RENASCENT II study showed no events at one year, while the DESolve Nx Study demonstrated a mean lumen gain of 9% at six months.
A study published by PCR found that TAVI significantly lowers the incidence of early stroke at 30 days and two years compared to surgical aortic valve replacement. The procedure also showed similar one-year mortality rates for both groups with stroke or encephalopathy at 30 days.
The EURO-CTO trial found that PCI had a higher procedural success rate (86.3%) and lower procedural risk compared to optimized medical therapy. Patients treated with PCI also showed significant improvements in clinical symptoms and quality of life, while those on medical therapy experienced less pronounced improvements.
A large dataset reports that deferring revascularization in patients with intermediate stenosis leads to fewer interventions. The rate of major adverse cardiovascular events (MACE) was low, especially in those without acute coronary syndromes.
The TOPIC study found that switching from a new P2Y12 inhibitor plus aspirin to maintenance DAPT with aspirin plus clopidogrel one month after acute coronary syndrome (ACS) significantly reduced bleeding risk, with a 70% lower rate of major bleeding events. Ischemic events remained similar between the two regimens.
Cardiologists from 115 countries gained knowledge and skills in treating cardiovascular disease through live demonstrations and educational sessions. They learned about the latest developments and best practices in coronary interventions, valvular disease, heart failure, peripheral interventions, and more.
The OPINION study shows that OFDI-guided PCI achieves equivalent clinical and angiographic outcomes to IVUS-guided PCI at 12 months. The study results contribute to defining the clinical value of OCT guidance in PCI.